The news items below are from oral presentations or poster sessions scheduled for the 50th annual ASCO conference.
Yale Cancer Center will have experts available to speak with the media before or during ASCO.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). (LBA #9003)